MacroGenics (MGNX) Competitors $3.23 +0.07 (+2.22%) As of 01/24/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MGNX vs. SEPN, AVDL, RLAY, PRTA, CRMD, SANA, REPL, QURE, PLRX, and PHARShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Septerna (SEPN), Avadel Pharmaceuticals (AVDL), Relay Therapeutics (RLAY), Prothena (PRTA), CorMedix (CRMD), Sana Biotechnology (SANA), Replimune Group (REPL), uniQure (QURE), Pliant Therapeutics (PLRX), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Septerna Avadel Pharmaceuticals Relay Therapeutics Prothena CorMedix Sana Biotechnology Replimune Group uniQure Pliant Therapeutics Pharming Group MacroGenics (NASDAQ:MGNX) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Do institutionals & insiders hold more shares of MGNX or SEPN? 96.9% of MacroGenics shares are owned by institutional investors. 11.3% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable earnings & valuation, MGNX or SEPN? Septerna has lower revenue, but higher earnings than MacroGenics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMacroGenics$58.75M3.45-$9.06M-$1.58-2.04SepternaN/AN/AN/AN/AN/A Does the MarketBeat Community favor MGNX or SEPN? MacroGenics received 422 more outperform votes than Septerna when rated by MarketBeat users. However, 100.00% of users gave Septerna an outperform vote while only 62.28% of users gave MacroGenics an outperform vote. CompanyUnderperformOutperformMacroGenicsOutperform Votes42662.28% Underperform Votes25837.72% SepternaOutperform Votes4100.00% Underperform VotesNo Votes Does the media refer more to MGNX or SEPN? In the previous week, Septerna had 7 more articles in the media than MacroGenics. MarketBeat recorded 7 mentions for Septerna and 0 mentions for MacroGenics. Septerna's average media sentiment score of 0.75 beat MacroGenics' score of -0.55 indicating that Septerna is being referred to more favorably in the news media. Company Overall Sentiment MacroGenics Negative Septerna Positive Do analysts recommend MGNX or SEPN? MacroGenics currently has a consensus target price of $7.63, suggesting a potential upside of 136.07%. Septerna has a consensus target price of $43.67, suggesting a potential upside of 136.29%. Given Septerna's stronger consensus rating and higher probable upside, analysts clearly believe Septerna is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36Septerna 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MGNX or SEPN more profitable? Septerna has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. Septerna's return on equity of 0.00% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets MacroGenics-69.07% -89.42% -38.57% Septerna N/A N/A N/A SummarySepterna beats MacroGenics on 9 of the 14 factors compared between the two stocks. Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$202.72M$6.74B$5.49B$9.21BDividend YieldN/A2.96%5.36%3.98%P/E Ratio-2.049.8788.6117.48Price / Sales3.45317.971,219.9278.46Price / CashN/A65.0944.3037.67Price / Book1.315.265.094.75Net Income-$9.06M$154.64M$117.69M$224.45M7 Day Performance7.67%4.75%3.18%1.47%1 Month Performance-0.92%2.39%4.06%3.31%1 Year Performance-74.77%10.23%28.46%22.21% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics3.7161 of 5 stars$3.23+2.2%$7.63+136.1%-73.1%$193.31M$58.75M-2.04430SEPNSepterna2.5091 of 5 stars$16.89-0.5%$43.67+158.5%N/A$749.92MN/A0.00N/AAnalyst RevisionNews CoverageAVDLAvadel Pharmaceuticals3.6645 of 5 stars$7.75-3.1%$21.00+171.0%-42.7%$746.79M$27.96M-9.8170RLAYRelay Therapeutics2.4159 of 5 stars$4.46+3.2%$20.50+359.6%-50.8%$746.52M$25.55M-1.71330Insider TradeNews CoverageGap DownHigh Trading VolumePRTAProthena2.6598 of 5 stars$13.77+4.5%$46.50+237.7%-52.6%$740.96M$91.37M-5.55130Analyst RevisionPositive NewsCRMDCorMedix2.3663 of 5 stars$12.17-4.8%$15.67+28.7%+288.1%$738.48M$60,000.00-15.0230Analyst ForecastSANASana Biotechnology3.0071 of 5 stars$3.16-2.8%$14.25+350.9%-36.5%$705.53MN/A-2.26380Gap DownREPLReplimune Group4.2601 of 5 stars$10.14-2.1%$17.29+70.5%+75.1%$693.78MN/A-3.32210Analyst ForecastAnalyst RevisionNews CoverageQUREuniQure3.9665 of 5 stars$14.05-1.1%$33.88+141.1%+177.3%$684.84M$28.59M-2.83500Analyst ForecastAnalyst RevisionPLRXPliant Therapeutics3.9692 of 5 stars$11.21-3.4%$40.50+261.3%-37.0%$682.13M$1.58M-3.3690Insider TradeAnalyst RevisionNews CoveragePHARPharming Group2.2753 of 5 stars$10.01+5.1%$27.00+169.7%-27.8%$678.98M$245.32M-38.50280 Related Companies and Tools Related Companies Septerna Alternatives Avadel Pharmaceuticals Alternatives Relay Therapeutics Alternatives Prothena Alternatives CorMedix Alternatives Sana Biotechnology Alternatives Replimune Group Alternatives uniQure Alternatives Pliant Therapeutics Alternatives Pharming Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MGNX) was last updated on 1/25/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGNX Stock Alerts